OR WAIT 15 SECS
July 19, 2016
The osteoporosis market in the Asia-Pacific (APAC) region, which covers India, China, Australia, South Korea and Japan, is set to grow from $4.5 billion in 2015 to $7.7 billion in 2022, according to GBI Research.
The company’s latest report states that this substantial growth can largely be attributed to the rising prevalence of osteoporosis, together with better diagnostic techniques, improving awareness, special healthcare programs for elderly populations, and increasing health insurance coverage.
In terms of new drugs, the late-stage osteoporosis pipeline contains promising anabolic and safer antiresorptive therapies that have the potential for approval and launch during the forecast period. Indeed, following the anticipated launch of anabolic therapies such as novel sclerostin inhibitors and human parathyroid hormone analogs, and first-in-class antiresorptive therapies such as cathepsin K inhibitors, the APAC osteoporosis market is likely to undergo rapid expansion.
GBI states that Amgen’s Romosozumab (AMG-785) is the most promising pipeline candidate due to its once-monthly dose and its ability to significantly increase lumbar spine bone mineral density from baseline at 11.3%, femoral neck at 3.7%, and total hip at 4.1%. It will be the second treatment option for patients undergoing anabolic treatment if approved before abaloparatide, and will address the largest patient subset: post-menopausal osteoporosis.